Item 1 of 2 An illustration of the packaging for Amgen Inc's Amjevita as well as the 40 milligram auto injector containing a bio similar version of AbbVie's Inc's Humira, the world's top selling ...

FILE - Packaging for AbbVie's drug, Humira, is photographed in Houston on July 18, 2014. Patients who take the autoimmune disease treatment may see some price relief when several lower-cost ...

How AbbVie’s Humira Still Reigns, Despite New Competition. Quarterly revenue for blockbuster arthritis drug declines, largely because of discounts for middlemen. By . David Wainer. Share.

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. It’s an ...

Humira, an arthritis medication with indications for colitis and psoriasis is the world’s best-selling drug, but while its efficacy and benefit to millions cannot be understated it has not been ...

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. But lower pharmacy… ...

AbbVie’s precursor, Abbott Laboratories, launched Humira in 2003 at $522 per two-week 40-milligram syringe. Within 10 years, that price jumped to $1,024 per syringe, according to a House ...

A U.S. appeals court on Monday affirmed that AbbVie Inc did not unlawfully block competition by building up a "thicket" of patents related to its blockbuster arthritis drug Humira.

Humira is a biologic drug, meaning it goes through a more complex manufacturing process than most drugs. Due to this complexity, competing companies can’t make exact replicas.

I n a significant victory for AbbVie, a U.S. appeals court panel declined to revive a lawsuit that accused the company of using a so-called patent thicket to forestall competition for its Humira ...